A sample processing method, blood analyzer

Abstract

The application discloses a sample processing method and a blood analyzer. The blood analyzer comprises a control module, a deagglomeration processing module and a test module. The control module is used for judging whether a sample is an agglomeration sample according to sample information of the sample. The deagglomeration processing module is used for automatically deagglomerating the agglomeration sample. The test module is used for detecting the processed agglomeration sample to obtain test information of the agglomeration sample. The control module is further used for generating a detection result of the agglomeration sample according to the test information. The blood analyzer can judge and process the abnormal sample according to the sample information, and the agglomeration sample processing does not need manual operation, thereby reducing the sample processing cost and improving the analysis efficiency of the blood analyzer.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of blood analysis, and in particular to a sample processing method and a blood analyzer. BACKGROUND

[0002] The blood analyzer is an instrument for detecting the number, volume and proportion of blood cells (red blood cells, white blood cells, platelets and hemoglobin) in blood. With the advancement of technology and the development of science and technology, the function of the blood analyzer is continuously expanding, the performance is continuously improving, and the degree of automation is continuously improving, and the blood analyzer is widely used in blood analysis.

[0003] Among them, when the blood analyzer detects blood cells, the blood cells are usually uniformly distributed in the blood sample, but when the agglutinin content is high or the sample temperature is too low, the blood cells uniformly suspended in the sample will gather into a group due to charge imbalance, causing blood cell agglutination, leading to deviation of the blood cell parameters from the actual value, and affecting the accuracy of the measurement results of the blood analyzer. The existing sample processing method needs to be manually identified and processed by the user when processing the blood cell agglutination sample, which is tedious, expensive in processing reagents and high in labor cost, and is not conducive to improving the analysis efficiency of the blood analyzer. SUMMARY

[0004] To solve the above technical problems, the present application provides a sample processing method and a blood analyzer.

[0005] To solve the above problems, the present application provides a sample processing method applied to a blood analyzer, which comprises: a control module acquires sample information of a sample and determines whether the sample is an agglutination sample according to the sample information; when the sample is an agglutination sample, the control module controls an agglutination resolving processing module to automatically resolve the agglutination of the agglutination sample; the control module controls a test module to detect the agglutination sample after processing to obtain test information of the agglutination sample; and the control module generates a detection result of the agglutination sample according to the test information.

[0006] To solve the above problems, the present application provides a blood analyzer, which comprises a control module, an agglutination resolving processing module and a test module; the control module is used to determine whether a sample is an agglutination sample according to sample information of the sample; the agglutination resolving processing module is used to automatically resolve the agglutination of the agglutination sample; the test module is used to detect the agglutination sample after processing to obtain test information of the agglutination sample; and the control module is further used to generate a detection result of the agglutination sample according to the test information.

[0007] The application provides a sample processing method and a blood analyzer, the blood analyzer comprising a control module, a deaggregation processing module and a test module; the control module is used for judging whether a sample is an aggregated sample according to sample information of the sample; the deaggregation processing module is used for automatically processing the aggregated sample; the test module is used for detecting the processed aggregated sample to obtain test information of the aggregated sample; and the control module is further used for generating a detection result of the aggregated sample according to the test information. The blood analyzer can judge and process the sample abnormally according to the sample information, and the aggregated sample processing does not need manual operation, thereby reducing the sample processing cost and improving the analysis efficiency of the blood analyzer. BRIEF DESCRIPTION OF DRAWINGS

[0008] In order to more clearly illustrate the technical solutions in the embodiments of the application, the drawings needed in the embodiment description will be briefly introduced. Obviously, the drawings in the following description are only some embodiments of the application, and other drawings can be obtained by those skilled in the art without creative effort. Among them:

[0009] Figure 1 is a structural schematic diagram of a first embodiment of the blood analyzer provided by the application;

[0010] Figure 2 is a structural schematic diagram of a second embodiment of the blood analyzer provided by the application;

[0011] Figure 3 is a flowchart of a first embodiment of the sample processing method provided by the application;

[0012] Figure 4 is a flowchart of a second embodiment of the sample processing method provided by the application;

[0013] Figure 5 is a flowchart of a third embodiment of the sample processing method provided by the application;

[0014] Figure 6 is a flowchart of a fourth embodiment of the sample processing method provided by the application;

[0015] Figure 7 is a flowchart of a fifth embodiment of the sample processing method provided by the application;

[0016] Figure 8 is a flowchart of a sixth embodiment of the sample processing method provided by the application;

[0017] Figure 9 is a flowchart of a seventh embodiment of the sample processing method provided by the application;

[0018] Figure 10 is a structural schematic diagram of a third embodiment of the blood analyzer provided in the present application;

[0019] Figure 11 is a structural schematic diagram of an embodiment of the computer readable storage medium provided in the present application. DETAILED DESCRIPTION

[0020] The technical solutions in the embodiments of the present application will be clearly and completely described in combination with the drawings in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, rather than all the embodiments of the present application. Based on the embodiments in the present application, all other embodiments obtained by a person of ordinary skill in the art without creative effort belong to the scope of protection of the present application.

[0021] It should be noted that if the present application embodiments involve directional indications (such as up, down, left, right, front, back, etc.), the directional indications are only used to explain the relative position relationship, movement condition, etc. between components in a certain posture (as shown in the drawings), and if the certain posture changes, the directional indications also change accordingly.

[0022] In addition, if the present application embodiments involve descriptions such as "first", "second", etc., the descriptions of "first", "second", etc. are only for description purposes, and cannot be understood as indicating or implying the relative importance of the indicated technical features or implicitly indicating the number of the indicated technical features. Therefore, the features limited by "first", "second" can explicitly or implicitly include at least one of the features. In addition, the technical solutions of each embodiment can be combined with each other, but it must be based on the fact that a person of ordinary skill in the art can realize it, and when the combination of technical solutions contradicts each other or cannot be realized, it should be considered that the combination of technical solutions does not exist, and is also not within the scope of protection claimed by the present application.

[0023] Therefore, the present application provides a sample processing method, which can be applied to a blood analyzer for counting cells in a blood sample to obtain parameters related to counting, and is used for processing a clotted sample of the blood analyzer to obtain a detection result of the clotted sample. Specifically, the sample processing method provided in the embodiments of the present application is used for judging whether a sample of the blood analyzer is a clotted sample, and is used for performing a de-clotting process on the clotted sample to obtain a detection result of the clotted sample.

[0024] Please refer to Figure 1 , Figure 1 is a structural schematic diagram of a first embodiment of the blood analyzer provided in the present application. As shown in Figure 1As shown, the blood analyzer comprises a control module 10, a deaggregation processing module 20, and a test module 30. The control module 10 is configured to determine whether a sample is an aggregated sample according to sample information of the sample. The deaggregation processing module 20 is configured to perform deaggregation processing on the aggregated sample. The test module 30 is configured to perform testing on the processed aggregated sample to obtain test information of the aggregated sample. The control module 10 is further configured to generate a test result of the sample according to the test information.

[0025] The aggregated sample includes, but is not limited to, a red blood cell aggregated sample, a white blood cell aggregated sample, and a PLT (platelet) aggregated sample. The deaggregation processing is configured to perform deaggregation operation on the aggregated blood cells of the aggregated sample, so that the blood analyzer can test the deaggregated blood cells and improve the accuracy of the testing. The deaggregation processing mode is different according to different sample objects. For example, when the aggregated sample is a red blood cell aggregated sample, the deaggregation processing is at least one of incubation processing, mixing processing, and dilution processing, so as to disperse the aggregated red blood cells for measurement. For example, when the aggregated sample is a PLT aggregated sample, the deaggregation processing is test channel conversion, which converts the test channel to a PLT-F channel for testing. The forward scattering light and the side fluorescence of the PLT are obtained by the semiconductor laser flow cytometry, a two-dimensional scatter plot is formed, and the PLT is counted more accurately.

[0026] Specifically, the control module 10 is connected with the deaggregation processing module 20 and the test module 30. The control module 10 is configured to control the abnormal processing flow of the deaggregation processing module 20 and the test flow of the test module 30. For example, the control module 10 is configured to control the deaggregation processing module 20 to perform deaggregation processing on the aggregated sample when the sample information indicates that the sample is an aggregated sample. The control module 10 is further configured to control the test module 30 to perform the test flow of the aggregated sample to obtain the test information of the aggregated sample after the deaggregation processing of the aggregated sample is completed. The control module 10 generates the test result of the aggregated sample according to the test information, so that the blood analyzer can automatically perform deaggregation processing on the aggregated sample without manual processing of the aggregated sample, thereby reducing the sample processing cost and improving the analysis efficiency of the blood analyzer.

[0027] Optionally, the test module 30 is further configured to perform testing on the sample to obtain sample information of the sample. The sample information includes, but is not limited to, red blood cell parameter information, platelet parameter information, white blood cell parameter information, histogram information, statistical scatter plot information, and aggregation image information of the sample.

[0028] Optionally, the disaggregation processing module 20 comprises at least one of an incubation assembly, a mixing assembly, and a dilution assembly; the incubation assembly is configured to perform an incubation process on the agglutination sample at a first preset temperature, the mixing assembly is configured to perform a mixing process on the agglutination sample, and the dilution assembly is configured to perform a dilution process on the agglutination sample at a first preset dilution ratio. The disaggregation processing performed by the disaggregation processing module 20 on the agglutination sample comprises at least one of the incubation process, the mixing process, and the dilution process.

[0029] Further, the blood analyzer is provided with at least one incubation site 230, which is configured to place the agglutination sample to perform the incubation process on the agglutination sample at the incubation site 230, so that the agglutination sample is subjected to the disaggregation process at the first preset temperature. The disaggregation processing module 20 is configured to perform the incubation process on the agglutination sample placed at the incubation site 230.

[0030] Specifically, the disaggregation processing module 20 comprises a heating assembly and a transfer assembly 210. The heating assembly is arranged at the incubation site 230 and is configured to heat the incubation site 230 to maintain the incubation site 230 at the first preset temperature. The transfer assembly 210 is configured to move the agglutination sample to the incubation site 230. The heating assembly can be a solid heat conduction type, which directly heats the test tube of the agglutination sample to maintain the incubation site 230 at the first preset temperature. Alternatively, the heating assembly can be a water bath heating type or an air bath heating type, which is not limited herein.

[0031] The first preset temperature is in the range of 35℃ to 43℃, for example, the first preset temperature can be 35℃, 36℃, 37℃, 38℃, 39℃, 40℃, 41℃, 42℃, or 43℃. The incubation process is performed for a time in the range of 5 minutes to 60 minutes, for example, the incubation process can be performed for 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, or 60 minutes.

[0032] When the incubation site 230 is maintained at the first preset temperature in the range of 35℃ to 43℃, the first preset temperature is close to the body temperature, so that the agglutination of the blood cells in the agglutination sample can be disaggregated at the first preset temperature. The longer the incubation process is performed, the better the disaggregation effect is, but the efficiency of sample analysis is lower. Therefore, the time of the incubation process can be controlled according to the agglutination degree of the agglutination sample and the sample analysis scheduling.

[0033] Optionally, the disaggregation processing module 20 comprises a dilution assembly, which is configured to perform a dilution process on the agglutination sample at a preset dilution ratio.

[0034] The preset multiple can be in the range of 60-1024, for example, the first preset multiple can be 60, 120, 250, 500 or 1000, for another example, the first preset multiple can be 64, 128, 256, 512 or 1024, and the first preset multiple can be selected according to the agglomeration degree of the agglomeration sample, which is not limited here.

[0035] The temperature of the dilution liquid is in the range of 33-38°C. Since the agglomeration sample is incubated in the range of 35-43°C, the control module 10 can heat the dilution liquid to keep its temperature in the range of 33-38°C before the dilution liquid is added to the dilution assembly, so as to be close to the temperature of the incubated agglomeration sample, thereby enhancing the effect of dilution and deagglomeration.

[0036] The dilution assembly includes a dilution pool 220 and a dilution liquid tank. The dilution pool 220 is used to contain the agglomeration sample and the dilution liquid, so as to react the dilution liquid with the agglomeration sample and dilute the agglomeration sample to a preset multiple. The dilution liquid tank is used to store the dilution liquid.

[0037] In an embodiment, the dilution pool 220 is a sample preparation pool of the blood analyzer, and the dilution pool 220 is also used to contain the sample and the dilution liquid to pre-dilute the sample. The test module 30 is used to detect the pre-diluted sample to obtain sample information. The sample of the blood analyzer needs to be mixed, pre-diluted and other pretreated before detection, and reagents such as dilution liquid and detection reagent are added to the sample preparation pool to obtain the sample to be detected in the sample preparation pool. The test module 30 detects the sample to be detected to obtain sample information. Specifically, the sample to be detected obtained by the sample preparation pool can be used for at least one of red blood cell detection, white blood cell detection, platelet detection and hemoglobin detection.

[0038] In other embodiments, the dilution pool 220 of the dilution assembly is only used for dilution treatment of the agglomeration sample, that is, the dilution pool 220 is used for dilution of the agglomeration sample, and the test module 30 further includes a sample preparation pool, which is used for preparation of the agglomeration sample or the sample before testing.

[0039] Optionally, the blood analyzer includes a sample adding module 40, and the sample adding module 40 includes a sample needle 430 and a power assembly.

[0040] In one embodiment, the dilution tank 220 is a sample preparation tank of the blood analyzer, the power assembly is connected with the sample preparation tank and the dilution liquid tank, and the power assembly is configured to add reagents such as dilution liquid and detection reagent into the sample preparation tank, for example, the power assembly includes but is not limited to a quantitative pump; the sample needle 430 is configured to transfer the agglutination sample to add the agglutination sample into the dilution tank 220, and the power assembly is configured to add a quantitative dilution liquid into the dilution tank 220. At this time, since the power assembly adds the dilution liquid quantitatively, the preset dilution multiple can be adjusted by adjusting the capacity of the agglutination sample transferred by the sample needle 430, so as to adjust the dilution multiple of the dilution assembly.

[0041] In another embodiment, the sample needle 430 is configured to add the dilution liquid and the sample into the dilution tank 220 to dilute the agglutination sample in the dilution tank 220 by a preset multiple. At this time, since the sample needle 430 can select the capacity of the dilution liquid and the sample to be delivered, the capacity of the sample and the dilution liquid can be adjusted when the dilution multiple of the agglutination sample is adjusted.

[0042] Optionally, referring to Figure 2 , Figure 2 is a structural schematic diagram of a second embodiment of the blood analyzer provided in the present application. As shown in Figure 2 , the sample adding module 40 is configured to obtain the agglutination sample after the disaggregation treatment and perform a sample preparation process on the agglutination sample, so that the test module 30 detects the agglutination sample.

[0043] Specifically, after the blood analyzer receives the sample, the transfer assembly 210 transfers the sample to the sample adding module 40, the sample adding module 40 is provided with a sample suction site 440, and the transfer assembly 210 is configured to move the sample to the sample suction site 440, so that the sample adding module 40 performs a sample preparation process on the agglutination sample at the sample suction site 440, so that the test module 30 detects the sample and obtains sample information of the sample; after the detection is completed, the control module 10 determines whether the sample is an agglutination sample according to the sample information, and controls the disaggregation treatment module 20 to perform a disaggregation treatment on the agglutination sample when it is determined that the sample is an agglutination sample; after the disaggregation treatment is completed, the transfer assembly 210 transfers the treated agglutination sample to the sample adding module 40, and the sample adding module 40 performs a sample preparation process on the agglutination sample, so that the test module 30 detects the agglutination sample, and obtains test information of the agglutination sample.

[0044] Optionally, the adding module 40 comprises a first mixing device 410, the first mixing device 410 is configured to mix the agglutination sample after the disaggregation treatment in a first mixing mode; the first mixing device 410 is also configured to mix the sample in a second mixing mode, so that the testing module 30 detects the mixed sample and obtains sample information; wherein the mixing strength of the first mixing mode is less than the mixing strength of the second mixing mode.

[0045] The sample preparation process of the adding module 40 at least comprises a pre-test mixing process, and the adding module 40 mixes the agglutination sample or the sample by the first mixing device 410. Specifically, after the blood analyzer receives the sample, the first mixing device 410 obtains the sample and mixes the sample in the second mixing mode, so that the testing module 30 performs a detection process on the mixed sample and obtains sample information; when the sample is an agglutination sample, the control module 10 controls the disaggregation treatment module 20 to perform the disaggregation treatment on the agglutination sample, and then the transfer assembly 210 transfers the agglutination sample after the disaggregation treatment to the first mixing device 410, so that the first mixing device 410 mixes the agglutination sample in the first mixing mode. Since the agglutination sample has been subjected to incubation treatment and / or dilution treatment of the disaggregation treatment module 20, in order to avoid the blood cells of the treated agglutination sample being damaged during the mixing process, the first mixing device 410 mixes the agglutination sample in the first mixing mode with a smaller mixing strength, thereby ensuring the reliability of the agglutination sample.

[0046] In an embodiment, the mixing mode of the first mixing device 410 is a gripper mixing mode, the first mixing device 410 grasps the sample or the agglutination sample by a gripper, and mixes the sample or the agglutination sample at a preset frequency and a preset posture. The frequency used in the first mixing mode is less than the frequency used in the second mixing mode.

[0047] Optionally, the blood analyzer comprises a sample input module, the sample input module is configured to receive the sample and obtain sample information of the sample, and the control module 10 is configured to determine that the sample is the agglutination sample after the disaggregation treatment according to the sample information, so that the adding module 40 obtains the agglutination sample.

[0048] The first mixing device 410 is also configured to obtain the sample from the sample input module. Specifically, after the sample input module receives the sample, the first mixing device 410 picks up the sample from the sample input module to mix the sample at a preset frequency and a preset posture. The transfer assembly 210 includes a transfer position 211 configured to carry a sample tube. The transfer assembly 210 is configured to move the sample at the transfer position 211 from a side close to the first mixing device 410 to the sample suction position 440. After the first mixing device 410 mixes the sample, the first mixing device 410 places the mixed sample on the transfer position 211. The transfer assembly 210 moves the sample to the sample suction position 440. The sample preparation module 40 performs a sample preparation process on the sample at the sample suction position 440. The testing module 30 detects the sample to obtain sample information of the sample. The control module 10 determines whether the sample is a clotted sample according to the sample information.

[0049] In this embodiment, since the incubation time is in the range of 5 minutes to 60 minutes, the time is relatively long. When the control module 10 determines that the sample is a clotted sample, the control module 10 obtains the use state of the incubation position 230. When all the incubation positions 230 of the blood analyzer are in the incubation state, the clotted sample cannot be placed in the incubation position 230 and moved to the incubation position 230. The blood analyzer can remove the clotted sample outside the machine. The blood analyzer marks the identification code corresponding to the clotted sample. The identification code of the clotted sample includes the marking information. The control module 10 sends a warning message to prompt the user to perform manual incubation on the clotted sample. After the user performs manual incubation on the clotted sample, the user places the clotted sample in the sample input module. The sample input module receives the sample according to the set sample input process and identifies the identification code of the sample. When the identification code of the sample includes the marking information, the control module 10 determines that the sample is an incubated clotted sample. The control module 10 controls other modules to perform subsequent operations on the incubated clotted sample. For example, the control module 10 can control the clotted sample resolving module 20 to perform dilution on the incubated clotted sample. Alternatively, the control module 10 can control the testing module 30 to detect the incubated clotted sample.

[0050] Alternatively, in an embodiment, the clotted sample resolving module 20 includes an incubation assembly. The incubation assembly is provided with at least one first incubation position 230. The incubation assembly is configured to incubate the clotted sample at the first incubation position 230 to resolve the clotted sample at a first preset temperature.

[0051] In another embodiment, the sample preparation module 40 includes a second mixing device 420. The second mixing device 420 is provided with a second incubation position 230. The second mixing device 420 is configured to incubate the clotted sample at the second incubation position 230 to resolve the clotted sample at a first preset temperature.

[0052] Specifically, according to different blood sampling methods, the sample test tubes suitable for the blood analyzer generally include micro blood test tubes and whole blood test tubes. After the whole blood test tube is received by the sample input module, the first mixing device 410 grasps the whole blood test tube by the gripper and mixes the whole blood test tube in the second mixing mode. Since the content of micro blood is less, the micro blood test tube has a double-layer structure, so that the first mixing device 410 cannot mix the micro blood test tube. Therefore, the blood analyzer is generally provided with a second mixing device 420, which is used for mixing the micro blood test tube. For example, the second mixing device 420 can mix the micro blood sample by periodically colliding with the micro blood test tube.

[0053] Since the existing blood analyzer generally has multiple detection items, the micro blood test tube of the blood analyzer is less, and the second mixing device 420 is generally in an idle state due to the influence of the detection items. Therefore, in the embodiment, the second mixing device 420 is multiplexed by using the micro blood mixing position of the second mixing device 420 for incubation of the agglutination sample, so that it is not necessary to set an independent incubation position 230 or reduce the number of incubation positions 230, which is beneficial to simplify the structure of the blood analyzer and reduce the volume of the blood analyzer.

[0054] It can be understood that the second mixing device 420 is used for incubation and / or mixing of the abnormal sample in the incubation position, that is, the second mixing device 420 is used for mixing of the agglutination sample or the micro blood sample, and / or the second mixing device 420 is used for incubation of the agglutination sample. The incubation of the agglutination sample can be performed on the first mixing position and / or the second mixing position. That is, the blood analyzer can be provided with at least one first mixing position, and the first mixing position is only used for the incubation process of the agglutination sample; or the blood analyzer can also incubate the agglutination sample by multiplexing the second mixing position of the second mixing device 420, without setting the first incubation position 230, so as to simplify the spatial structure of the blood analyzer and reduce the volume of the blood analyzer; or when the agglutination sample is more, the blood analyzer can also be provided with at least one first mixing position and second mixing position at the same time, so that the agglutination sample can be incubated at the same time, and the efficiency of the abnormal processing is improved.

[0055] The second mixing device 420 is configured to mix the trace blood sample in the third mixing mode and mix the agglutination sample in the second incubation position 230 in the fourth mixing mode. When the blood analyzer incubates the agglutination sample by the second mixing device 420, in order to improve the speed of the agglutination sample, the control module 10 can control the second mixing device 420 to mix the incubated agglutination sample during the incubation process. In order to prevent the rupture of the blood cells of the agglutination sample during the incubation process, the mixing strength of the fourth mixing mode is less than that of the third mixing mode, so as to ensure the accuracy of the sample analysis result.

[0056] The mixing strength of the second mixing device 420 can be embodied in the mixing amplitude, the mixing strength, the motor power used by the second mixing device 420, etc., which is not limited here.

[0057] Optionally, the first mixing device 410 is configured to grasp the agglutination sample in the first incubation position 230, and / or the first mixing device 410 is configured to grasp the agglutination sample in the second incubation position 230 to move the agglutination sample to the transfer assembly 210, so that the transfer assembly 210 transfers the incubated agglutination sample to other modules or assemblies.

[0058] In order to facilitate the grasping of the agglutination sample, the first incubation position 230 is a position of the grasping track of the first mixing device 410, and / or in order to facilitate the sample preparation process of the agglutination sample by the sample adding module 40, the first incubation position 230 is a position of the movement track of the sample adding module 40.

[0059] Optionally, the test module 30 comprises an abnormality detection assembly configured to detect the abnormality of the sample to obtain the sample information. The abnormality detection assembly detects the abnormality of the sample to obtain the agglutination image information of the sample. The abnormality detection assembly is configured to obtain the agglutination image information of the sample, so that the control module 10 can determine whether the sample is an agglutination sample according to the agglutination image information. The abnormality detection assembly includes but is not limited to a camera.

[0060] Please refer to Figure 3 , Figure 3 is a flowchart of the first embodiment of the sample processing method provided by the present application. As shown in Figure 3 , the blood analyzer of the embodiment of the present application can comprise a test module 30, a control module 10 and an agglutination dissociation processing module 20. The control module 10 is connected with the test module 30 and the agglutination dissociation processing module 20, and is configured to control the execution process of the test module 30 and the agglutination dissociation processing module 20. The sample processing method of the embodiment comprises the following steps:

[0061] Step S11: The control module 10 acquires sample information of the sample, and determines whether the sample is a clotted sample according to the sample information.

[0062] In an optional embodiment, before step S11, the sample processing method comprises the following steps: the control module 10 controls the sample receiving module 40 to receive the sample; and the control module 10 controls the test module 30 to detect the sample to obtain sample information of the sample.

[0063] According to different detection items, the blood analyzer has multiple test components; for example, the test module 30 at least comprises a first test component and a second test component, the first test component and the second test component are used to perform test procedures of different detection items on the sample. In an embodiment, after the sample is sent into the blood analyzer, any one of the first test component and the second test component of the blood analyzer performs test on the sample to obtain sample information of the sample, and the control module 10 determines whether the sample is a clotted sample according to the sample information. For example, the sample information can be blood cell parameter information or histogram information of a blood cell count test; when the test module 30 performs sample test by means of laser scattering and fluorescence staining, the sample information can also be a statistical scatter plot of various cells, etc.

[0064] In other embodiments, the test module 30 further comprises an abnormality detection component, before the test module 30 performs detection on the sample, the control module 10 controls the abnormality detection component to perform abnormality detection on the sample to obtain sample information of the sample and determine whether the sample is a clotted sample according to the sample information. The clotted sample includes but is not limited to a red blood cell clotted sample, a white blood cell clotted sample, a platelet clotted sample, and a hemoglobin clotted sample.

[0065] Step S12: When the sample is a clotted sample, the control module 10 controls the clotted sample to be automatically processed by the clotted sample resolving processing module 20.

[0066] After the control module 10 acquires the sample information, it determines whether the sample is a clotted sample according to the sample information. When the sample is a normal sample, the control module 10 moves the sample to the corresponding test module 30 to perform detection on the sample. When the sample is a clotted sample, the control module 10 controls the clotted sample resolving processing module 20 to perform clotted sample resolving processing on the clotted sample. The clotted sample resolving processing mode is related to the sample object; for example, when the clotted sample is a red blood cell clotted sample, the clotted sample resolving processing is a resolving processing; when the clotted sample is a PLT clotted sample, the clotted sample resolving processing is a test channel conversion.

[0067] It can be understood that the automatic processing of the disaggregation processing module 20 is embodied in that the disaggregation processing module 20 can automatically perform disaggregation processing on the sample when it is determined that the sample is a clotted sample. Since the analysis process of the blood analyzer in the embodiment is an automatic process, and the disaggregation processing can also be automatically performed when the sample is a clotted sample, the judgment and processing of the clotted sample do not need to be manually performed, the automatic efficiency of the blood analyzer is effectively improved, and the labor cost is reduced.

[0068] Step S13: The control module 10 controls the test module 30 to test the processed clotted sample to obtain test information of the clotted sample.

[0069] After the disaggregation processing of the clotted sample is performed, the control module 10 controls the test module 30 to test the processed clotted sample to obtain test information of the clotted sample. The control module 10 can control at least one of the first test component and the second test component to test the clotted sample. For example, the sample information is obtained by testing the sample once through the first test component, and the first test component is controlled to test the processed clotted sample twice to determine whether the processed clotted sample is disaggregated effectively according to the test information.

[0070] Step S14: The control module 10 generates a detection result of the clotted sample according to the test information.

[0071] The test information can be a parameter result of a blood cell count test. When the test module 30 tests the sample by a laser scattering and fluorescence staining method, the test information can also be a statistical scatter plot of various cells, etc. The specific type of the test information is related to the detection item of the test module 30, which is not specifically limited here. After the control module 10 obtains the test information of the clotted sample, the detection result of the clotted sample is generated according to the test information. The detection result can include the test information and prompt information obtained by the control module 10 according to the test information. For example, the prompt information can include a disaggregation processing scheme of the clotted sample, an effective degree of the disaggregation processing, and related suggestion information, etc.

[0072] In the embodiment, the control module 10 determines whether the sample is a clotted sample according to the sample information of the sample. When the sample is a clotted sample, the control module 10 controls the disaggregation processing module 20 to perform disaggregation processing on the clotted sample, controls the test module 30 to detect the processed clotted sample to obtain test information of the clotted sample, and generates a detection result of the clotted sample according to the test information. The sample processing method in the embodiment can determine and process the abnormal sample according to the sample information, without manually processing the clotted sample, thereby reducing the sample processing cost and improving the analysis efficiency of the blood analyzer.

[0073] Optionally, when the agglutination sample is a red blood cell agglutination sample, in an embodiment, the step S12 comprises the following steps: when the sample is an agglutination sample, the control module 10 controls the deagglutination processing module 20 to move the agglutination sample to the incubation position 230; the control module 10 controls the temperature of the incubation position 230 to deagglutinate the agglutination sample at a first preset temperature.

[0074] Specifically, blood cells are agglutinated due to factors such as low temperature and abnormal lectin, and the volume of the blood cells changes abnormally, so that when the blood analyzer detects the sample, the red blood cell count changes falsely, affecting the detection accuracy of the blood analyzer. Therefore, when the control module 10 detects that the sample is an agglutination sample, in order to ensure the detection accuracy of the agglutination sample, the agglutination sample needs to be deagglutinated.

[0075] The control module 10 controls the deagglutination processing module 20 to move the agglutination sample to the incubation position 230, and the control module 10 controls the temperature of the incubation position 230 to deagglutinate the agglutination sample at a first preset temperature. The first preset temperature can be in the range of 35-43°C.

[0076] The control module 10 controls the deagglutination processing module 20 to incubate the agglutination sample for a preset time, and after the incubation is completed, the control module 10 controls the test module 30 to test the agglutination sample to determine whether the incubation is effective in deagglutination. If the incubation is not effective in deagglutination, the control module 10 can output an alarm information, or the control module 10 can control the deagglutination processing module 20 to continue deagglutination processing of the agglutination sample.

[0077] In another embodiment, please refer to Figure 4 , Figure 4 is a flowchart of a second embodiment of the sample processing method provided by the present application. As shown in Figure 4 , in the present embodiment, the deagglutination processing module 20 comprises a dilution assembly for diluting the agglutination sample, and the step S12 comprises the following steps:

[0078] Step S21: When the sample is an agglutination sample, the control module 10 controls the deagglutination processing module 20 to move the agglutination sample to the incubation position 230.

[0079] When the sample is an agglutination sample, the control module 10 controls the deagglutination processing module 20 to move the agglutination sample to the incubation position 230 to incubate the agglutination sample for a preset time.

[0080] Step S22: The control module 10 controls the temperature of the incubation position 230 to deagglutinate the agglutination sample at a first preset temperature.

[0081] The control module 10 controls the temperature of the incubation position 230 to make the agglutination sample be deagglutinated at a first preset temperature. The first preset temperature is in a range of 35-43 DEG C, for example, the first preset temperature can be 35 DEG C, 36 DEG C, 37 DEG C, 38 DEG C, 39 DEG C, 40 DEG C, 41 DEG C, 42 DEG C or 43 DEG C, the first preset temperature is close to the human body temperature to simulate the environment of the blood sample in the human body and accelerate the deagglutination speed of the agglutination sample.

[0082] Step S23: The control module 10 controls the sample adding module 40 to add the incubated agglutination sample and the diluent to the dilution assembly to dilute the agglutination sample in the dilution assembly by a first preset multiple.

[0083] Specifically, the blood analyzer further comprises a sample adding module 40 connected with the control module 10. After the incubation of the agglutination sample is completed, the control module 10 controls the sample adding module 40 to add the incubated agglutination sample to the dilution assembly and add the diluent to the dilution assembly to dilute the agglutination sample in the dilution assembly by a first preset multiple, so that the cell spacing of the diluted agglutination sample is increased to deagglutinate the agglutinated blood cells. The first preset multiple is in a range of 60-1024.

[0084] The order of adding the agglutination sample and the diluent by the sample adding module 40 can be adding the agglutination sample first or adding the diluent first, and the dilution by the first preset multiple can be achieved by adjusting the addition amount of the agglutination sample or adjusting the addition amount of the diluent, and the order and the addition amount are not limited herein.

[0085] In the embodiments of the present application, the sample processing method can incubate and / or dilute the agglutination sample to reduce the agglutination degree of the agglutination sample, reduce the influence of the agglutination sample on the detection parameters, and improve the analysis efficiency of the blood analyzer.

[0086] Optionally, before the control module 10 controls the sample adding module 40 to add the agglutination sample and the diluent, the control module 10 controls the dilution assembly to heat the diluent to a second preset temperature, and the second preset temperature is in a range of 28-38 DEG C. After the diluent is preheated, the temperature of the diluent is close to the temperature of the agglutination sample to enhance the deagglutination effect of the dilution.

[0087] Further, after the deagglutination processing module 20 performs the corresponding abnormal processing measures on the agglutination sample, the control module 10 controls the test module 30 to test the processed agglutination sample to obtain test information of the agglutination sample, and generates a corresponding detection result according to the test information.

[0088] Specifically, in one embodiment, the disaggregation processing module 20 incubates the agglutination sample to disaggregate the agglutinated blood cells at a first preset temperature. At this time, the control module 10 controls the test module 30 to test the incubated agglutination sample to obtain first test information of the agglutination sample, the first test information being a test parameter of the agglutination sample, for example, when the agglutination sample is a red blood cell agglutination sample, the first test information can include at least one of mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV), hematocrit (HCT), red blood cell count (RBC), and mean corpuscular hemoglobin (MCH). The control module 10 determines whether the agglutination titer of the incubated agglutination sample is within a preset range according to the parameters of the first test information, and further obtains the detection result of the agglutination sample.

[0089] For example, when the first test information includes the MCHC parameter, it can be determined whether the agglutination titer of the agglutination sample is high by determining whether the MCHC is greater than a first preset value, for example, the first preset value can be 360 g / L or 380 g / L, when the MCHC is greater than 360 g / L or 380 g / L, the agglutination titer of the agglutination sample is high, and blood cell agglutination occurs in the agglutination sample; when the first test information includes the MCV parameter, it can be determined that the agglutination titer of the agglutination sample is high by determining whether the MCV is high; when the first test information includes the HCT parameter, it can be determined that the agglutination titer of the agglutination sample is high by determining whether the HCT is low; when the first test information includes the RBC parameter, it can be determined that the agglutination titer of the agglutination sample is high by determining whether the RBC is low; when the first test information includes the MCH parameter, it can be determined that the agglutination titer of the agglutination sample is high by determining whether the MCH is high, for example, whether the MCH is greater than a second preset value, the second preset value can be 33 pg; when the first test information includes the HGB and RBC parameters, the condition for determining that the agglutination titer of the agglutination sample is high is whether the first ratio of HGB and RBC is greater than a third preset value, for example, the third preset value can be 30. It can be understood that the above-mentioned various determination methods can be combined arbitrarily, for example, the agglutination titer of the agglutination sample can be determined according to the first ratio of HGB and RBC, MCH, MCHC, or other parameters, and the determination method of the agglutination titer of the agglutination sample is not limited here.

[0090] In another embodiment, the disaggregation processing module 20 performs incubation processing on the agglutination sample, and performs dilution processing on the agglutination sample after incubation. At this time, the control module 10 controls the test module 30 to perform testing on the agglutination sample after dilution to obtain second test information of the agglutination sample. Similarly, when the agglutination sample is a red blood cell agglutination sample, the second test information can include at least one of mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV), hematocrit (HCT), red blood cell count (RBC), and mean corpuscular hemoglobin (MCH). The control module 10 determines whether the agglutination titer of the agglutination sample after dilution is within a preset range according to the parameters of the second test information, and further obtains the detection result of the agglutination sample.

[0091] In yet another embodiment, please refer to Figure 5 , Figure 5 is a flowchart of a third embodiment of the sample processing method provided by the present application. As shown in Figure 5 , the disaggregation processing module 20 performs incubation processing on the agglutination sample to obtain first test information of the agglutination sample, and step S14 includes the following steps:

[0092] Step S31: The control module 10 responds to the first test information not satisfying the first preset condition, and takes the first test information as the detection result.

[0093] Specifically, the first test information is a test parameter of the agglutination sample after incubation, and the control module 10 determines whether the agglutination titer of the agglutination sample after incubation is high through the first test information. The first preset condition is used to determine the agglutination state of the agglutination sample. When the first test information satisfies the first preset condition, the agglutination sample after incubation still has blood cell agglutination, and the agglutination titer of the agglutination sample is high. When the first test information does not satisfy the first preset condition, the agglutination titer of the agglutination sample after incubation is low, and the degree of blood cell agglutination is low or there is no blood cell agglutination. At this time, the first test information is taken as the detection result.

[0094] The first preset condition is related to the parameters of the first test information, and the first preset condition can include one or more of the above-mentioned judgment methods for determining the agglutination titer of the agglutination sample after incubation according to the first test information, and the first preset condition is not limited here. When the first test information satisfies the first preset condition, the agglutination titer of the agglutination sample after incubation is low, and the control module 10 takes the first test information as the detection result of the agglutination sample.

[0095] Step S32: The control module 10 responds to the first test information not satisfying the first preset condition, and controls the disaggregation processing module 20 to perform dilution processing on the agglutination sample after incubation.

[0096] When the first test information does not satisfy the first preset condition, it indicates that the agglutination titer of the incubated agglutination sample is high, and the control module 10 controls the deagglutination processing module 20 to perform dilution processing on the incubated agglutination sample. The specific dilution method and steps S23 are similar, and will not be repeated here. After the dilution processing is completed, the control module 10 controls the test module 30 to detect the diluted agglutination sample to obtain second test information, and takes the second test information as the detection result of the agglutination sample.

[0097] In the embodiment, the control module 10 selects whether to perform dilution processing on the incubated agglutination sample according to the first test information, so as to reduce the time consumption of abnormal processing and improve the analysis efficiency of the blood analyzer.

[0098] Optionally, in an embodiment, when the deagglutination processing module 20 performs dilution processing on the agglutination sample, the dilution multiple is in the range of 60-1024. The deagglutination processing module 20 can obtain the agglutination type information of the agglutination sample by performing dilution processing on the agglutination sample with different dilution multiples. The control module 10 outputs the detection result according to the test information and the agglutination type information, so that the user can view the agglutination type, deagglutination scheme and deagglutination effect of the agglutination sample through the detection result. For example, the agglutination type of the agglutination sample includes physiological agglutination and pathological agglutination. Here, 512 times of dilution multiple is taken as the standard for judging different agglutination types. After the deagglutination processing module 20 performs dilution processing on the agglutination sample with 512 times or less (for example, 256 times, 128 times, etc.), the control module 10 obtains the test information of the diluted agglutination sample. When the test information indicates that the agglutination titer of the agglutination sample diluted by 512 times or less is high, the control module 10 determines that the agglutination type of the agglutination sample is pathological agglutination. When the deagglutination processing module 20 performs dilution processing on the agglutination sample with 512 times or more (for example, 512 times, 1024 times, etc.), the control module 10 obtains the test information of the diluted agglutination sample. When the test information indicates that the agglutination titer of the agglutination sample diluted by 512 times or more is low, the control module 10 determines that the agglutination type of the agglutination sample is physiological agglutination.

[0099] For example, after the disaggregation processing module 20 performs the first dilution processing on the agglutination sample at a dilution ratio of less than 512 times (e.g., 256 times, 128 times, etc.), the control module 10 obtains the test information of the agglutination sample after the first dilution processing. When the test information indicates that the agglutination titer of the agglutination sample after the first dilution processing is high, the disaggregation processing module 20 performs the second dilution processing on the agglutination sample at a dilution ratio of 512 times or more (e.g., 512 times, 1024 times, etc.), and the control module 10 obtains the test information of the agglutination sample after the second dilution processing. When the test information indicates that the agglutination titer of the agglutination sample after the second dilution processing is low, the control module 10 determines that the agglutination type of the agglutination sample is physiological agglutination, and otherwise, the agglutination type is pathological agglutination.

[0100] It can be understood that the disaggregation processing module 20 of the embodiment can obtain the agglutination type information of the agglutination sample by performing dilution processing on the agglutination sample at different dilution ratios, so that the user can determine the agglutination type of the agglutination sample, facilitate the user to take different processing measures on the agglutination sample, and improve the user experience.

[0101] Optionally, in the present embodiment, the incubation site 230 includes at least a first incubation site 230 and a second incubation site 230. The first incubation site 230 is arranged in the incubation assembly, and the second incubation site 230 is arranged in the second mixer 420.

[0102] Please refer to Figure 6 , Figure 6 is a flowchart of a fourth embodiment of the sample processing method provided by the present application. As shown in Figure 6 , in the present embodiment, the step of the control module 10 controlling the disaggregation processing module 20 to move the agglutination sample to the incubation site 230 for incubation processing includes:

[0103] Step S41: When the sample is an agglutination sample, the control module 10 obtains the use state of the second incubation site 230.

[0104] Specifically, a detector can be arranged at the second incubation site 230 for detecting the use state of the second incubation site 230. For example, the detector can be an optical coupling detector to detect whether the second incubation site 230 has an agglutination sample.

[0105] Step S42: In response to the use state being an idle state, the control module 10 controls the disaggregation processing module 20 to move the agglutination sample to the second incubation site 230.

[0106] When the usage state of the second incubation site 230 is the idle state, the control module 10 controls the deagglutination processing module 20 to move the agglutination sample to the second incubation site 230. Specifically, the second mixing device 420 is used for mixing the micro blood test tube, and is arranged on one side close to the first mixing device 410, so that the first mixing device 410 transfers the micro blood test tube of the sample loading module to the second mixing device 420. Therefore, when the usage state of the second incubation site 230 is the idle state, the control module 10 preferentially uses the second incubation site 230 to incubate the agglutination sample, which can facilitate the grabbing operation of the first mixing device 410, reduce the transfer time of the agglutination sample, and improve the efficiency of the abnormal processing.

[0107] Step S43: The control module 10 controls the deagglutination processing module 20 to move the agglutination sample to the first incubation site 230 in response to the usage state being the incubation state.

[0108] When the usage state of the second incubation site 230 is the incubation state, that is, the second incubation site 230 has other agglutination samples being incubated, the control module 10 controls the deagglutination processing module 20 to move the agglutination sample to the first incubation site 230, so as to incubate the agglutination sample by the first incubation site 230.

[0109] In the embodiment of the present application, the control module 10 controls the deagglutination processing module 20 to move the agglutination sample to the second incubation site 230 in response to the usage state of the second incubation site 230 being the idle state, so as to facilitate the grabbing operation of the first mixing device 410, reduce the transfer time of the agglutination sample, and improve the efficiency of the abnormal processing.

[0110] Optionally, in other embodiments, the blood analyzer is provided with at least one first incubation site 230 and one second incubation site 230, and the control module 10 can alternately move the agglutination sample to the first incubation site 230 or the second incubation site 230 according to a preset order. For example, when the incubation assembly is provided with two first incubation sites 230, the control module 10 incubates the agglutination sample in the order of the first incubation site 230, the first incubation site 230, and the second incubation site 230.

[0111] Optionally, please refer to Figure 7 , Figure 7 is a flow diagram of the fifth embodiment of the sample processing method provided by the present application. As shown in Figure 7 , in the embodiment, step S12 includes the following steps:

[0112] Step S51: The control module 10 unloads the agglutination sample from the blood analyzer in response to the usage state of the incubation site 230 being the incubation state, so that the agglutination sample is incubated outside the blood analyzer.

[0113] Similarly, the incubation site 230 can be provided with a detector for detecting the use state of the incubation site 230. For example, the detector can be an optical coupling detector for detecting whether the incubation site 230 has an agglutination sample. When the incubation site 230 has an agglutination sample, that is, the use state of the incubation site 230 is an incubation state, the control module 10 unloads the agglutination sample from the blood analyzer and sends a prompt message to the visual interface, so that the user receives the prompt message and manually incubates the agglutination sample.

[0114] Step S52: The control module 10 controls the sample module to receive the sample, and controls the sample module to perform a scanning operation on the test tube carrying the sample to obtain the identification information of the sample.

[0115] When the control module 10 unloads the agglutination sample, the control module 10 can mark the identification code of the agglutination sample. For example, the control module 10 can add the identification code of the agglutination sample to the exception list. After the manual incubation of the agglutination sample is completed, the user moves the test tube carrying the agglutination sample to the sample module again, so that the sample module performs a scanning operation on the identification code of the test tube to obtain the identification information of the sample. For another example, the control module 10 can mark the identification code corresponding to the agglutination sample, so that the identification code of the agglutination sample includes the marking information.

[0116] Step S53: The control module 10 determines whether the sample is an incubated agglutination sample according to the identification information.

[0117] After the control module 10 obtains the identification information, it determines whether the identification information includes the marking information or whether the identification information is in the exception list, to determine whether the sample is an incubated agglutination sample. It can be understood that the identification information can be image information of the identification code.

[0118] Step S54: The control module 10 controls the deagglomeration processing module 20 to perform a dilution process on the agglutination sample in response to the sample being an incubated agglutination sample.

[0119] When the identification information includes the marking information or the identification information is in the exception list, the control module 10 determines that the sample corresponding to the identification information is an incubated agglutination sample. At this time, the control module 10 controls the deagglomeration processing module 20 to perform a dilution process on the agglutination sample.

[0120] When the incubation position 230 of the blood analyzer is less, or when the agglutination samples of the blood analyzer are more, the situation that multiple agglutination samples need to be incubated may occur. Since the incubation process usually takes 5-60 minutes, which is time-consuming, in the embodiment, the control module 10 can unload the agglutination samples from the blood analyzer when the use state of the incubation position 230 is the incubation state, so that the incubation process of the agglutination samples is performed outside the blood analyzer, and the agglutination samples do not need to wait, thereby improving the efficiency of the abnormal processing.

[0121] Further, before step S23, and / or before step S54, the sample processing method further includes: controlling the test module to test the incubated agglutination sample to obtain first test information of the agglutination sample. Step S13 includes: controlling the test module 10 to test the diluted agglutination sample to obtain second test information of the agglutination sample; and controlling the control module 10 to determine whether the agglutination titer of the diluted agglutination sample is within a preset range according to the first test information and the second test information, thereby obtaining a detection result of the agglutination sample.

[0122] After obtaining the first test information and the second test information, step S14 further includes: controlling the control module 10 to take the second test information or the first test information as the detection result in response to the first test information and the second test information not satisfying a first preset condition; and controlling the control module 10 to generate a warning information in response to the first test information and the second test information satisfying the first preset condition.

[0123] In the embodiment, the agglutination sample is a red blood cell agglutination sample, and the first test information and the second test information at least include RBC, MCHC, MCV, HCT, and MCH parameters. 、 It can be understood that the first preset condition is used to determine whether the incubated agglutination sample and the diluted agglutination sample have blood cell agglutination according to the first test information and the second test information, and the first preset condition can be one of the determination methods or a combination of multiple determination methods as described in the above embodiments.

[0124] When the first test information and the second test information do not satisfy the first preset condition, i.e., the first agglutination titer and the second agglutination titer are both low, the blood cell agglutination degree of the incubated agglutination sample and the diluted agglutination sample is not high or no blood cell agglutination occurs, the control module 10 further acquires a second ratio of the RBC parameters of the diluted agglutination sample and the incubated agglutination sample, and selects the first test information or the second test information as the detection result of the agglutination sample according to the second ratio. When the second ratio of the diluted RBC and the incubated RBC is greater than a fourth preset value, the dilution treatment has a certain deagglutination effect, and the control module 10 selects the second test information as the detection result of the agglutination sample; when the second ratio of the diluted RBC and the incubated RBC is less than or equal to the fourth preset value, the deagglutination effect of the dilution treatment is poor, and the control module 10 selects the first test information as the detection result of the agglutination sample; wherein the fourth preset value can be set according to the sensitivity of the agglutination judgment of the blood analyzer, for example, the fourth preset value can be set to 1.1 or 1.2, which is not limited herein.

[0125] When the first test information and the second test information satisfy the first preset condition, i.e., the first agglutination titer and the second agglutination titer are both high, or the first agglutination titer or the second agglutination titer is high, the blood cell agglutination degree of at least one of the incubated agglutination sample and the diluted agglutination sample is high, which indicates that the deagglutination treatment of the deagglutination treatment module 20 is not obvious. At this time, the control module 10 generates a warning information.

[0126] Further, the control module 10 generates a warning information, which can be displayed on the visual interface of the blood analyzer for the user to view. In an optional embodiment, the warning information can include a plurality of selection instructions, and the agglutination sample is processed according to the selection of the user on the plurality of selection instructions, for example, the selection instructions can include a first selection instruction for instructing the control module 10 to perform a secondary deagglutination treatment on the agglutination sample and a second selection instruction for instructing the control module 10 to exit the agglutination sample from the blood analyzer, which is not limited herein.

[0127] The control module 10 controls the deagglutination treatment module 20 to perform a secondary deagglutination treatment on the agglutination sample in response to the warning information. The secondary deagglutination treatment can be any deagglutination scheme as described above, for example, the control module 10 controls the agglutination sample to be incubated for a second time in response to the warning information, to increase the incubation time of the agglutination sample, and / or controls the agglutination sample to be diluted by a second dilution multiple, which is greater than the first dilution multiple, to further increase the cell spacing of the agglutination sample under the dilution of the second dilution multiple, and increase the effect of the deagglutination treatment.

[0128] In the optional embodiment, according to the conditions of the first agglutination titer and the second agglutination titer, the blood analyzer can select different secondary dilution processing schemes; for example, when the first agglutination titer of the incubated agglutination sample is high and the second agglutination titer of the diluted agglutination sample is low, the control module 10 can further obtain the second ratio of the RBC parameters of the diluted agglutination sample and the incubated agglutination sample, and when the second ratio is greater than a fourth preset value, it indicates that the dilution processing has a certain deagglutination effect, and the control module 10 can respond to the warning information to control the deagglutination processing module 20 to perform dilution processing on the agglutination sample again at a second dilution multiple, which is greater than the first dilution multiple, to further increase the cell spacing of the agglutination sample, and then control the test module 30 to test the agglutination sample to obtain the detection result as the final detection result; when the first agglutination titer of the incubated agglutination sample is low and the second agglutination titer of the diluted agglutination sample is high, it indicates that the dilution multiple selected when the incubated agglutination sample is diluted is too large, resulting in the increase of the agglutination titer of the agglutination sample. At this time, the control module 10 can respond to the warning information to control the deagglutination processing module 20 to perform dilution processing on the agglutination sample again at a third dilution multiple, which is less than the first dilution multiple.

[0129] Optionally, the test information includes at least one of blood cell count information, blood cell volume information, hemoglobin information, and hematocrit information of the agglutination sample. For example, when the agglutination sample is a red blood cell agglutination sample, the test information of the agglutination sample includes at least one of mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV), hematocrit (HCT), red blood cell count (RBC), and mean corpuscular hemoglobin content (MCH).

[0130] Optionally, after the step of controlling the sample module 40 to receive the sample by the control module 10, the sample processing method further includes: controlling the first mixing device 410 to mix the sample in the second mixing mode; and controlling the sample needle 430 to sample the mixed sample, so that the test module 30 detects the sample.

[0131] Optionally, the step S14 includes: controlling the first mixing device 410 to obtain the agglutination sample and mix the agglutination sample in the first mixing mode, the mixing strength of the first mixing mode being less than that of the second mixing mode; and controlling the sample needle 430 to sample the mixed agglutination sample and controlling the test module 30 to detect the sampled agglutination sample to obtain the detection result of the agglutination sample.

[0132] See Figure 8 , Figure 8is a flowchart of a sixth embodiment of the sample processing method provided in the present application. As shown in Figure 8 The sample processing method of the present embodiment includes the following steps:

[0133] Step S61: The control module 10 controls the test module 30 to detect the sample to obtain sample information of the sample.

[0134] Specifically, the sample information is related to the detection manner of the test module 30 on the sample. The test module 30 includes multiple test components, for example, the test module 30 can include a first test component for performing impedance detection, a second test component for performing specific protein detection, in an embodiment, the control module 10 controls the first test component to detect the sample to obtain red blood cell parameter information of the sample, the red blood cell parameters include MCHC, MCV, HCT, RBC and MCH, or the control module 10 controls the first test component to perform red blood cell detection or platelet detection on the sample to obtain histogram information; in another embodiment, the control module 10 controls the second test component to detect the sample to obtain statistical information of the blood cells of the sample, such as statistical scatter diagram; in still another embodiment, the test module 30 includes an abnormality detection component, which performs abnormality detection on the sample to obtain agglutination image information of the sample.

[0135] Step S62: The control module 10 determines whether the sample is an agglutination sample according to the sample information.

[0136] Specifically, after obtaining the sample information such as red blood cell parameter information, histogram information, statistical information or agglutination image information, the control module 10 determines whether the sample is an agglutination sample according to the sample information.

[0137] Step S63: The control module 10 controls the deagglutination processing module 20 to perform deagglutination processing on the agglutination sample in response to the sample being an agglutination sample.

[0138] The control module 10 controls the deagglutination processing module 20 to perform deagglutination processing on the agglutination sample in response to the sample being an agglutination sample, the deagglutination processing includes incubation processing and / or dilution processing. For example, in an embodiment, the deagglutination processing is that the deagglutination processing module 20 performs incubation processing on the agglutination sample; in another embodiment, the deagglutination processing is that the deagglutination processing module 20 performs incubation processing on the agglutination sample and performs dilution processing on the agglutination sample after incubation; in still another embodiment, the incubation positions 230 of the blood analyzer are all in the incubation process, the user performs manual incubation processing on the agglutination sample outside the blood analyzer, the blood analyzer receives the agglutination sample after incubation, the deagglutination processing module 20 performs dilution processing on the agglutination sample, and the control module 10 can control the deagglutination processing module 20 to perform different deagglutination processing processes on the agglutination sample according to the sample information or user instructions.

[0139] Step S64: The control module 10 controls the test module 30 to detect the processed agglutination sample to obtain a detection result of the agglutination sample.

[0140] After the deagglutination processing module 20 deagglutinates the agglutination sample, the control module 10 controls the test module 30 to detect the processed agglutination sample to obtain test information of the agglutination sample, and generates a detection result of the agglutination sample according to the test information. The specific method of obtaining the detection result in step S74 is similar to the above method, and is not described here.

[0141] In the embodiments of the present application, the control module 10 controls the test module 30 to detect the sample to obtain sample information of the sample, and controls the deagglutination processing module 20 to deagglutinate the agglutination sample when the sample is an agglutination sample according to the sample information of the sample. The control module 10 controls the test module 30 to detect the processed agglutination sample to obtain test information of the agglutination sample, and generates a detection result of the agglutination sample according to the test information. The sample processing method of the present embodiment can judge and process the abnormal sample according to the sample information, without manual agglutination sample processing, thereby reducing the sample processing cost and improving the analysis efficiency of the blood analyzer.

[0142] Optionally, step S62 includes: the control module 10 determines that the sample is an agglutination sample in response to the sample information not satisfying the first preset condition.

[0143] Specifically, in an embodiment, when the sample information includes red blood cell parameter information, for example, when the red blood cell parameter includes MCHC, whether the sample is an agglutination sample can be determined by judging whether the MCHC is greater than a first preset value, and the first preset value includes but is not limited to 360 mg / L or 380 mg / L; when the red blood cell parameter includes MCV, whether the sample is an agglutination sample can be determined by judging whether the MCV is high; when the red blood cell parameter includes HCT, whether the sample is an agglutination sample can be determined by judging whether the HCT is low; when the red blood cell parameter includes HCT, whether the sample is an agglutination sample can be determined by judging whether the HCT is low; when the red blood cell parameter includes MCH, whether the sample is an agglutination sample can be determined by judging whether the MCH is greater than a second preset value, and the second preset value includes but is not limited to 33 pg; and when the red blood cell parameter includes RBC and HGB, whether the sample is an agglutination sample can be determined by judging whether a first ratio of HGB and RBC is greater than a third preset value, and the third preset value includes but is not limited to 30.

[0144] In another embodiment, when the sample information includes histogram information of red blood cell detection or platelet detection, the histogram usually has cell volume as the abscissa and cell quantity as the ordinate, and whether the sample is an agglomeration sample can be determined by judging the waveform symmetry of the histogram.

[0145] In another embodiment, when the sample information includes statistical scatter diagram information for cell classification, the scatter diagram usually has side fluorescence signal as the abscissa and forward scattering light signal as the ordinate, and the agglomeration sample can be determined by judging the aggregation shape, intensity distribution, etc. of blood cells in the statistical scatter diagram.

[0146] It can be understood that the above various determination methods can be combined in any manner, for example, the MCV parameter and the HCT parameter can be used as the determination basis for the agglomeration sample; or the first ratio of HGB and RBC, the MCH, the MCHC, etc. can be used as the determination basis for the agglomeration sample; or the statistical scatter diagram, the histogram, and the red blood cell parameter information can be combined to be used as the determination basis for the agglomeration sample. According to the use scene, the detection time sequence of the blood analyzer for different detection items, and the sensitivity of the agglomeration determination, different determination manners can be selected to determine the agglomeration sample, and the first preset condition is not specifically limited herein.

[0147] Optionally, the step S63 includes the following steps: the control module 10 obtains the agglomeration degree of the agglomeration sample according to the sample information; and the control module 10 controls the deagglomeration processing module 20 to perform deagglomeration processing on the agglomeration sample according to the agglomeration degree.

[0148] Specifically, after the control module 10 determines that the sample is an agglomeration sample according to the sample information, the agglomeration degree of the agglomeration sample is obtained, and the deagglomeration processing module 20 is controlled to perform corresponding deagglomeration processing on the agglomeration sample according to the agglomeration degree. It can be understood that the deagglomeration processing module 20 includes a plurality of deagglomeration processing schemes, each deagglomeration processing scheme corresponds to the agglomeration degree of the agglomeration sample, when the agglomeration degree of the agglomeration sample is low, the deagglomeration processing module 20 selects a deagglomeration processing scheme with low processing degree, for example, the deagglomeration processing scheme includes incubation processing and dilution processing, and the lower deagglomeration processing scheme can be an incubation processing scheme with shorter incubation time and / or a dilution processing scheme with lower dilution multiple.

[0149] Further, please refer to Figure 9 , Figure 9 is a flowchart of the seventh embodiment of the sample processing method provided by the present application. As shown in Figure 9 , the step S63 includes the following steps:

[0150] Step S71: The control module 10 judges whether the sample information meets the second preset condition, and the range of the second preset condition is smaller than the range of the first preset condition.

[0151] In the embodiment, the control module 10 judges the sample information according to the first preset condition before judging whether the sample information meets the second preset condition, that is, the control module 10 judges the sample according to the second preset condition after the sample information meets the first preset condition.

[0152] The second preset condition is similar to the first preset condition in the above embodiment. For example, when the control module 10 judges whether the sample is a clumping sample according to whether the MCHC parameter is greater than a first preset value, the control module 10 can judge whether the sample information meets the second preset condition according to whether the MCHC is greater than a fifth preset value, the fifth preset value is greater than the first preset value, for example, the first preset value is 380 mg / L, and the fifth preset value is 400 mg / L, the range of the first preset condition is (380, ∞), and the range of the second preset condition is (400, ∞), the limit range of the second preset condition is smaller than that of the first preset condition.

[0153] Step S72: When the sample information does not meet the second preset condition, the control module 10 determines that the clumping sample is at the first clumping degree.

[0154] When the sample information does not meet the second preset condition, for example, when the second preset condition is judged according to the MCHC parameter, the MCHC parameter is greater than 380 mg / L and less than or equal to 400 mg / L, which means that the sample information does not meet the second preset condition, the clumping degree of red blood cells of the clumping sample is low, and the control module 10 determines that the clumping sample is at the first clumping degree.

[0155] Step S73: When the sample information meets the second preset condition, the control module 10 determines that the clumping sample is at the second clumping degree.

[0156] When the sample information meets the second preset condition, for example, when the second preset condition is judged according to the MCHC parameter, the MCHC parameter is greater than 400 mg / L, which means that the sample information meets the second preset condition, the clumping degree of red blood cells of the clumping sample is high, and the control module 10 determines that the clumping sample is at the second clumping degree.

[0157] It can be understood that, according to the sample information selected according to the first preset condition, there are multiple ways to judge whether the sample information meets the second preset condition, for example, when the control module 10 judges whether the sample is a clumping sample according to the waveform symmetry of the histogram information, the clumping degree of the clumping sample can be judged by judging the waveform symmetry degree of the histogram information, and the second preset condition is not limited herein.

[0158] In the embodiments of the present application, the sample processing method can obtain the agglomeration degree of the agglutinated sample according to the sample information, so that the control module 10 can execute the corresponding abnormal processing scheme according to different agglomeration degrees, to avoid unnecessary deagglomeration processing of the low agglomeration degree sample, reduce the time consumption of abnormal processing, and improve the analysis efficiency of the blood analyzer.

[0159] In an optional embodiment, the step of deagglomeration processing module 20 deagglomeration processing the agglutinated sample according to the agglomeration degree comprises: in response to the agglutinated sample being at the first agglomeration degree, the control module 10 controls the deagglomeration processing module 20 to perform incubation processing on the agglutinated sample at a first preset temperature; in response to the agglutinated sample being at the second agglomeration degree, the control module 10 controls the deagglomeration processing module 20 to perform incubation processing on the agglutinated sample, and controls the deagglomeration processing module 20 to perform dilution processing on the agglutinated sample after the incubation processing at a first preset multiple.

[0160] Specifically, when the agglutinated sample is at the second agglomeration degree, the deagglomeration processing comprises the following steps: the control module 10 controls the deagglomeration processing module 20 to perform incubation processing on the agglutinated sample at a first preset temperature; the control module 10 adds the incubated agglutinated sample to the dilution assembly; the control module 10 adds the diluent to the dilution assembly to dilute the agglutinated sample at a first preset multiple, so that the agglutinated sample is deagglomerated under the dilution at the first preset multiple.

[0161] Further, when the deagglomeration processing module 20 processes the agglutinated sample, the diluent needs to be heated to a second preset temperature before being added to the dilution assembly.

[0162] In another optional embodiment, after step S83, the sample processing method further comprises: the control module 10 judges whether the sample information satisfies a third preset condition, the range of the third preset condition being smaller than the range of the second preset condition; when the sample information satisfies the third preset condition, the control module 10 determines that the agglutinated sample is at a third agglomeration degree.

[0163] Similarly, the third preset condition is similar to the second preset condition and the first preset condition described above. When the control module 10 judges whether the sample information meets the third preset condition, the sample information meets the second preset condition and the first preset condition. For example, when the control module 10 judges whether the sample is a clumping sample according to whether the MCHC parameter is greater than the first preset value, the control module 10 can judge whether the sample information meets the third preset condition according to whether the MCHC is greater than the sixth preset value. For example, the first preset value is 380 mg / L, the fifth preset value is 400 mg / L, and the sixth preset value is 420 mg / L. The range of the first preset condition is (380, ∞), the range of the second preset condition is (400, ∞), and the range of the third preset condition is (420, ∞). The limit range of the third preset condition is smaller than the limit range of the second preset condition.

[0164] When the sample information meets the third preset condition, for example, when the MCHC parameter of the sample information is greater than 420 mg / L, it indicates that the sample information meets the third preset condition, and the clumping degree of the red blood cells of the clumping sample is high. The control module 10 determines that the clumping sample is in the third clumping degree.

[0165] The step of the de-clumping processing module 20 performing de-clumping processing on the clumping sample according to the clumping degree includes: in response to the clumping sample being in the first clumping degree, the control module 10 controls the de-clumping processing module 20 to perform incubation processing on the clumping sample at the first preset temperature; in response to the clumping sample being in the second clumping degree, the control module 10 controls the de-clumping processing module 20 to perform incubation processing on the clumping sample, and controls the de-clumping processing module 20 to perform dilution processing on the clumping sample after the incubation processing at the first preset multiple; in response to the clumping sample being in the third clumping degree, the control module 10 controls the de-clumping processing module 20 to perform dilution on the clumping sample at the second preset multiple, and the second preset multiple is greater than the first preset multiple.

[0166] It can be understood that the greater the dilution multiple, the better the de-clumping effect of the blood cell clumping sample. When the clumping sample is in the third clumping degree, the second preset multiple is greater than or equal to 500 times. For example, the first preset multiple is 250 times, and the second preset multiple is 500 times; or the first preset multiple is 500 times, and the second preset multiple is 1000 times.

[0167] In other embodiments, the step of the disaggregation processing module 20 performing the disaggregation processing on the agglutination sample according to the agglutination degree can further include: in response to the agglutination sample being at the first agglutination degree, the control module 10 controls the disaggregation processing module 20 to perform the incubation processing on the agglutination sample at a first preset temperature, so as to make the agglutination sample disaggregate within a first preset time; in response to the agglutination sample being at the second agglutination degree, the control module 10 controls the disaggregation processing module 20 to perform the incubation processing on the agglutination sample at the first preset temperature, so as to make the agglutination sample disaggregate within a second preset time, the second preset time being greater than the first preset time.

[0168] Specifically, when the disaggregation processing procedure of the disaggregation processing module 20 is the incubation processing, according to the different agglutination degrees, the control module 10 can control the disaggregation processing module 20 to perform the incubation processing on the agglutination sample for different lengths of time. The second preset time and the first preset time are both within the range of 5 minutes to 60 minutes, and the second preset time is greater than the first preset time. For example, when the agglutination sample is at the first agglutination degree, the control module 10 controls the disaggregation processing module 20 to perform the incubation processing on the agglutination sample for a first preset time, which can be 10 minutes; when the agglutination sample is at the second agglutination degree, the control module 10 controls the disaggregation processing module 20 to perform the incubation processing on the agglutination sample for a second preset time, which can be 30 minutes.

[0169] Optionally, the sample information includes parameter information, and the parameter information includes at least one of red blood cell count information, red blood cell volume information, hemoglobin information, and hematocrit information of the sample.

[0170] Optionally, the sample information includes agglutination image information. In this embodiment, the step S62 includes the following steps: the control module 10 acquires the agglutination image information, and matches the agglutination image information with preset characteristic information; when the matching degree of the agglutination image information and the preset characteristic information is greater than a preset threshold, the control module 10 determines that the sample is the agglutination sample.

[0171] Specifically, when the sample is the blood cell agglutination sample, the sample will exhibit the characteristics of blood cell agglutination, for example, the sample solution exhibits the characteristics of sand or granules. In this embodiment, the control module 10 can determine whether the sample is the agglutination sample through the agglutination image information of the sample. The preset characteristic information is the characteristic information of the blood cell agglutination sample, for example, the preset characteristic information can be the sand characteristic information of the blood cell agglutination sample. The control module 10 matches the agglutination image information with the preset characteristic information, so as to determine the agglutination sample according to the matching degree of the agglutination image information and the preset characteristic information.

[0172] The control module 10 can detect or identify the relevant features, states and attributes of the agglomeration image information by means of various vision-related algorithms, so as to obtain the matching degree of the agglomeration image information and the preset feature information. The vision-related algorithms can involve vision positioning, SLAM, background segmentation, key point extraction and tracking of objects, etc. The control module 10 can detect or identify the relevant features, states and attributes of the target object by means of a convolutional neural network. For example, the convolutional neural network is a network model obtained by model training based on a deep learning framework.

[0173] Further, when the agglomeration degree of the agglomeration sample is obtained according to the sample information, the agglomeration degree of the agglomeration sample can be obtained by comparing the matching degree of the agglomeration image information and the preset feature information with a plurality of preset thresholds.

[0174] Please refer to Figure 10 , Figure 10 is a structural schematic diagram of a third embodiment of the blood analyzer provided in the present application. As Figure 10 shown, the blood analyzer 100 comprises a processor 101 and a memory 102 connected to the processor 101, wherein the memory 102 stores program data, and the processor 101 calls the program data stored in the memory 102 to execute the above-mentioned sample processing method.

[0175] Optionally, in an embodiment, the processor 101 is configured to execute the program data to implement the following method: the control module 10 obtains sample information of a sample, and determines whether the sample is an agglomeration sample according to the sample information; when the sample is an agglomeration sample, the control module 10 controls the deagglomeration processing module 20 to perform deagglomeration processing on the agglomeration sample; the control module 10 controls the test module 30 to detect the processed agglomeration sample to obtain test information of the agglomeration sample; and the control module 10 generates a detection result of the agglomeration sample according to the test information.

[0176] Optionally, in another embodiment, the processor 101 is configured to execute the program data to implement the following method: the control module 10 controls the test module 30 to detect a sample to obtain sample information of the sample; the control module 10 determines whether the sample is an agglomeration sample according to the sample information; the control module 10 controls the deagglomeration processing module 20 to perform deagglomeration processing on the agglomeration sample in response to the sample being an agglomeration sample; and the control module 10 controls the test module 30 to detect the processed agglomeration sample to obtain a detection result of the agglomeration sample.

[0177] The processor 101 can also be referred to as a CPU (Central Processing Unit). The processor 101 can be an electronic chip with signal processing capability. The processor 101 can also be a general-purpose processor, a DSP (Digital Signal Processor), an ASIC (Application-Specific Integrated Circuit), an FPGA (Field Programmable Gate Array) or other programmable logic device, a discrete gate or transistor logic device, a discrete hardware component. The general-purpose processor can be a microprocessor or the processor can also be any conventional processor.

[0178] The memory 102 can be a memory stick, a TF card, etc. It can store all information in the blood analyzer 100, including input raw data, computer programs, intermediate running results and final running results. It stores and retrieves information according to the location specified by the processor 101. With the memory 102, the blood analyzer 100 has a memory function and can work normally. The memory 102 of the blood analyzer 100 can be divided into main memory (internal memory) and auxiliary memory (external memory) according to its purpose. There are also classification methods of external memory and internal memory. The external memory is usually a magnetic medium or an optical disc, etc. which can store information for a long time. The internal memory refers to the storage component on the motherboard, which is used to store the data and programs currently being executed, but only for temporary storage of programs and data. When the power is off or disconnected, the data will be lost.

[0179] Please refer to Figure 11 , Figure 11 is a structural schematic diagram of an embodiment of the computer readable storage medium provided by the present application. As Figure 11 shown, the computer readable storage medium 110 stores program instructions 111 capable of implementing all the methods described above.

[0180] The functional units integrated in the various embodiments of the present application can be stored in the computer readable storage medium 110 if they are realized in the form of software functional units and sold or used as independent products. Based on this understanding, the technical solutions of the present application or the whole or part of the technical solutions that essentially contribute to the prior art can be embodied in the form of a software product. The computer readable storage medium 110 includes a plurality of instructions in a program instruction 111 to make a computer device (which can be a personal computer, a system server, or a network device, etc.), an electronic device (such as MP3, MP4, etc., which can also be a mobile terminal such as a mobile phone, a tablet computer, a wearable device, etc., or a desktop computer, etc.) or a processor to execute all or part of the steps of the various embodiments of the present application.

[0181] Those skilled in the art will appreciate that embodiments of the application can be readily used as a method, a system or a computer program product. Accordingly, the application can take the form of an entirely hardware embodiment, an entirely software embodiment or an embodiment combining software and hardware aspects. Furthermore, the application can take the form of a computer program product on one or more computer readable storage media (including, but not limited to, disk memory, CD-ROMs, optical storage devices, etc.) having computer usable program code embodied therein.

[0182] The present application is described in reference to the flowchart illustrations and / or block diagrams of methods, apparatus (systems) and computer program products according to embodiments of the application. It will be understood that each block of the flowchart illustrations and / or block diagrams, and combinations of blocks in the flowchart illustrations and / or block diagrams, can be implemented by computer readable storage media 110. The computer readable storage media 110 can be provided to a processor of a general purpose computer, special purpose computer, an embedded processor or other programmable data processing apparatus to produce a machine, such that the instructions that are produced in the computer readable storage media 110, when accessed by a processor of the computer or other programmable data processing apparatus, produce a machine implemented process that implements the flowchart illustrations and / or block diagrams. Figure 1 one or more functions specified in the flow or flows and / or block or blocks. Figure 1 one or more functions specified in the flow or flows and / or block or blocks.

[0183] The computer readable storage media 110 can also be loaded onto a computer or other programmable data processing apparatus to cause a series of operational steps to be performed on the computer or other programmable apparatus to produce a computer implemented process such that the instructions that are executed on the computer or other programmable apparatus provide steps for implementing the flowchart illustrations and / or block diagrams. Figure 1 one or more functions specified in the flow or flows and / or block or blocks. Figure 1 one or more functions specified in the flow or flows and / or block or blocks.

[0184] The computer readable storage media 110 can also be loaded onto a computer or other programmable data processing apparatus to cause a series of operational steps to be performed on the computer or other programmable apparatus to produce a computer implemented process such that the instructions that are executed on the computer or other programmable apparatus provide steps for implementing the flowchart illustrations and / or block diagrams. Figure 1 one or more functions specified in the flow or flows and / or block or blocks. Figure 1 Figure 1 one or more functions specified in the flow or flows and / or block or blocks.

[0185] Any processes or methods described in the flow charts or otherwise described herein can be understood as representing modules, segments, or portions of code that include one or more executable instructions for implementing specific logic functions or steps, and the preferred embodiments of the present application include additional implementations in which the functions are performed in a different order, in substantially simultaneous fashion, or in reverse order, and the scope of the embodiments of the present application should be understood to include such additional implementations.

[0186] The logic and / or steps represented in the flow charts or otherwise described herein, for example, can be considered as a list of executable instructions for implementing the logic function, and can be embodied in any computer-readable medium for use by or in connection with an instruction execution system, apparatus, or device, such as a personal computer, server, network device, or other processing device, that can fetch the instructions from the instruction execution system, apparatus, or device, and execute the instructions.

[0187] The above description is merely illustrative of the embodiments of the present application and is not in any way limiting of the patent scope of the present application, and any equivalent structures or equivalent processes transformed by using the content of the specification and drawings of the present application, or directly or indirectly applied to other related technical fields, are also included in the patent protection scope of the present application.

Claims

1. A blood analyzer, characterized in that, include: The control module is used to determine whether the sample is an agglutinated sample based on the sample information. A deagglomeration processing module is used to automatically deagglomerate the agglomerated samples; The testing module is used to test the processed agglutinated sample to obtain test information of the agglutinated sample. The control module is also used to generate the detection results of the agglutinated sample based on the test information; The blood analyzer includes a second mixer with a second incubation position. The second mixer is used to mix a small amount of blood sample in a third mixing mode. It is also used to incubate an agglutinated sample located in the second incubation position to disagglutinate the agglutinated sample at a first preset temperature. Furthermore, the second mixer is used to mix the agglutinated sample located in the second incubation position using a fourth mixing mode while the agglutinated sample is being incubated. The mixing intensity of the fourth mixing mode is less than that of the third mixing mode. The control module controls the testing module to detect the incubated agglutinated sample to obtain first test information about the agglutinated sample. The deagglomeration processing module further includes a dilution component, which is used to dilute the incubated agglomerated sample by a first preset factor. The control module is used to control the testing module to test the diluted agglomerated sample to obtain second test information of the agglomerated sample. The control module is configured to, in response to the first test information and the second test information not meeting the first preset condition, take the second test information or the first test information as the detection result; and in response to the first test information and the second test information meeting the first preset condition, generate a warning message; the control module is further configured to: when the first test information indicates a high first agglutination titer and the second test information indicates a low second agglutination titer, obtain a second ratio of the RBC parameters of the diluted agglutinated sample and the incubated agglutinated sample; When the second ratio is greater than the fourth preset value, in response to the warning information, the dilution component is controlled to perform a second dilution process on the agglutinated sample, the second dilution factor being greater than the first dilution factor; the test module is controlled to test the agglutinated sample diluted by the second dilution factor, so that the test information of the agglutinated sample diluted by the second dilution factor is used as the detection result of the agglutinated sample.

2. The blood analyzer according to claim 1, characterized in that, The first preset temperature is in the range of 35℃ to 43℃, and the incubation time is in the range of 5 minutes to 60 minutes.

3. The blood analyzer according to claim 1, characterized in that, The first preset multiple is in the range of 60 to 1024.

4. The blood analyzer according to claim 1, characterized in that, The temperature of the diluent in the dilution process is in the range of 33℃ to 38℃.

5. The blood analyzer according to claim 1, characterized in that, The dilution assembly includes a dilution pool for containing the agglutinated sample and a diluent to dilute the agglutinated sample to the preset multiple; and / or, the dilution pool for containing the sample and a diluent to pre-dilute the sample, and the testing module for testing the pre-diluted sample to obtain sample information.

6. A sample processing method using a blood analyzer as described in any one of claims 1-5, characterized in that, include: The control module acquires the sample information of the sample and determines whether the sample is an agglutinated sample based on the sample information; When the sample is an agglomerated sample, the control module controls the deagglomeration processing module to perform automated deagglomeration processing on the agglomerated sample; The control module controls the testing module to test the processed agglutinated sample in order to obtain test information of the agglutinated sample. The control module generates the detection results of the agglutinated sample based on the test information.

Images